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Introduction: This study compared the efficacy of pemetrexed in
patients with anaplastic lymphoma kinase (ALK)-positive versus ALK-
negative (epidermal growth factor receptor [EGFR] mutant or wild type
[WT] for both ALK and EGFR) non-small cell lung cancer (NSCLC).
Methods: Patients with advanced NSCLC who received second-line
pemetrexed and beyond between March 2007 and April 2010 were
screened for EGFR mutations and ALK rearrangements at Seoul
National University Hospital. The clinical and in vitro efficacy of
pemetrexed was evaluated for each genotypic group.
Results: Ninety-five NSCLC patients were genotyped as follows: 43
(45%) EGFR mutation, 15 (16%) ALK translocation, and 37 (39%)
WT. The overall response rate was superior in ALK-translocated
patients compared with EGFR mutant or WT patients (46.7 versus
4.7 versus 16.2%, p  0.001). ALK-positive patients showed longer
time to progression than EGFR mutant or WT patients (9.2 versus
1.4 versus 2.9 months, p  0.001). ALK positivity alone was a
significant predictor for overall response rate (hazard ratio [HR] 
0.07, 95% confidence interval [CI]: 0.01–0.32; p  0.001) and time
to progression (HR  0.44, 95% CI: 0.24–0.80; p  0.007). ALK
positivity remained independently significant regardless of treatment
line (HR  0.43, 95% CI: 0.24–0.77; p  0.005). Thymidylate
synthase mRNA levels in ALK-positive cells were significantly
lower compared with control cells (p  0.05).
Conclusion: Pemetrexed is an effective treatment in patients with
ALK-positive NSCLC. ALK positivity was independently predictive
of pemetrexed efficacy in NSCLC patients.
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Lung adenocarcinoma is heterogeneous with diverse so-matic mutations associated with carcinogenesis.1 Most
East Asian patients with lung adenocarcinoma who have
never smoked harbor targetable oncogenic mutations, includ-
ing epidermal growth factor receptor (EGFR) mutations,
fusions of echinoderm microtubule-associated protein-like 4
(EML4) and anaplastic lymphoma kinase (ALK), and human
epidermal growth factor receptor 2.2 The discovery of these
mutations led to the era of targeted therapies. Recent phase III
studies showed that first-line treatment with gefitinib length-
ened survival time in patients with lung adenocarcinoma with
EGFR mutations.3,4
An EML4-ALK fusion transcript derived from a small
inversion within chromosome 2p has a transforming activity.5
Tumors of EML4-ALK transgenic mice were effectively
cleared by an ALK inhibitor, indicating that ALK inhibition
shows strong therapeutic potential in patients with ALK-
rearranged non-small cell lung cancer (NSCLC) (overall
response rate [ORR], 57%; disease control rate (DCR) at 8th
week, 87%; and 6-month progression-free survival, 72%).6
Several studies have shown that ALK-translocated
NSCLC was most common in patients of younger age,
patients with adenocarcinoma, and patients who never or
lightly smoked.5,7–10 Only one study has examined treatment
outcomes of patients with ALK translocation.7 ALK-positive
NSCLC patients did not respond to EGFR TKIs and showed
a similar response rate to platinum-based agents compared
with wild-type (WT) patients. Therefore, typical clinical and
pathologic findings, as well as responsiveness to EGFR TKIs,
are useful in identifying ALK-translocated NSCLC patients.
However, considering the low frequency of EML4-ALK
translocation in NSCLC (3–13%),5,7,8 it is crucial to find
novel clinical features for ALK-positive lung cancer.
Pemetrexed is a multitargeted antifolate that inhibits
thymidylate synthase (TS), dihydrofolate reductase, glyci-
namide ribonucleotide formyltransferase, and aminoimida-
zole carboxamide ribonucleotide formyltransferase. Pem-
etrexed prevents the formation of precursor pyrimidine and
purine nucleotides.
Pemetrexed is currently approved for treatment of patients
with nonsquamous cell histology as a first-line treatment in
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combination with platinum,11,12 as a second-line single agent,13
and as maintenance therapy after first-line platinum-based che-
motherapy.14 In addition, pemetrexed showed modest efficacy
as a third- or fourth-line treatment.15,16
A recent study demonstrated that pemetrexed plus cis-
platin significantly prolonged time to progression (TTP) (9
versus 6.2 months) and overall survival (17 versus 11
months) in ALK-positive NSCLC patients, compared with
ALK-negative patients, suggesting a potential role of pem-
etrexed in ALK-rearranged cases.17 Therefore, this retrospec-
tive study was designed to compare the efficacy of pem-
etrexed between ALK-positive and ALK-negative cases and to
identify features associated with treatment outcome in ALK-
translocated NSCLC.
PATIENTS AND METHODS
Study Population
Korean patients with advanced NSCLC who received
pemetrexed between March 2007 and April 2010 were iden-
tified from the database at Seoul National University Hospi-
tal. Patients were invited to participate in this study if they
met all of the following inclusion criteria: (1) single-agent
pemetrexed therapy, as a second-line, third-line, or subse-
quent treatment; (2) genotypic screening for EGFR mutation
and EML4-ALK fusion; (3) histologically confirmed NSCLC
at stage IIIB/IV or relapse; (4) at least one prior systemic
chemotherapy, including platinum-based doublet; and (5)
adequate bone marrow, renal, and hepatic functions. Ten
and three ALK-positive patients were enrolled in phase I
(NCT00585195)6 and phase II (NCT00932451) trials of cr-
izotinib (PF-02341066), respectively. Patients enrolled in the
phase III trial (NCT00932893) were excluded because it was
designed to compare the efficacy of PF-02341066 versus
pemetrexed or docetaxel. Patients were categorized by their
smoking histories. A never-smoker was defined as a patient
who had smoked 100 cigarettes in their lifetime. Former
light-smokers were defined as patients who had a history of
10 pack-years of smoking.7 This study was approved by the
Institutional Review Board of Seoul National University
Hospital.
Determination of Molecular Subtypes
Patients were divided to three groups according to
molecular subtype: EGFR mutation, ALK translocation, and
WT. ALK positivity was defined as split signals 15% by
TABLE 1. Patients’ Characteristics Based on Genotype
Characteristic
No. of Patients (%)
p
Total
(n  95)
ALK Translocation
(n  15)
EGFR Mutation
(n  43)
Wild Type
(n  37)
Age, yr
Median 58 52 63 56 0.043
Range 28–79 34–67 34–79 28–79
Sex
Male 44 (46.3) 7 (46.7) 20 (46.5) 17 (45.9) 0.998
Female 51 (53.7) 8 (53.3) 23 (53.5) 20 (54.1)
PS
0–1 91 (95.8) 14 (93.3) 42 (97.7) 35 (94.6) 0.695
2–3 4 (3.2) 1 (6.7) 1 (2.3) 2 (5.4)
Smoking
Never 59 (62.1) 8 (53.3) 28 (65.1) 23 (62.2) 0.099
Light 7 (7.4) 0 6 (14.0) 1 (2.7)
Former/current 29 (30.5) 7 (46.7) 9 (20.9) 13 (35.1)
Histology
Adenocarcinoma 78 (82.1) 14 (93.3) 37 (86.0) 27 (73.0) 0.282
Nonadenocarcinomaa 17 (17.9) 1 (6.7) 6 (14.0) 10 (27.0)
Stage
IA 1 (1.1) 0 1 (2.3) 0 0.408
IB 8 (8.4) 3 (20.0) 3 (7.0) 2 (5.4)
IIB 2 (2.1) 0 2 (4.7) 0
IIIA 6 (6.3) 1 (6.7) 2 (4.7) 3 (8.1)
IIIB 7 (7.4) 0 2 (4.7) 5 (13.5)
IV 71 (74.7) 11 (73.3) 33 (76.6) 27 (73.0)
Pemetrexed
Second-line 38 (40.0) 6 (40.0) 6 (14.0) 26 (70.3) 0.001
 Third-line 57 (60.0) 9 (60.0) 37 (86.0) 11 (29.7)
a Nonadenocarcinoma included adenosquamous, squamous, large cell carcinoma, and non-small cell lung cancer, not otherwise specified
(NSCLC, NOS). One wild-type patient had squamous cell carcinoma.
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; PS, performance status.
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break-apart fluorescent in situ hybridization (FISH).6 The
EGFR mutant group harbored an activating mutation on exon
19 or 21. WT patients were neither EGFR mutant nor ALK
positive. EGFR mutations on exons 18, 19, 20, and 21 were
determined by direct DNA sequencing.18
Dual-probe hybridization for ALK was performed using
the LSI ALK break-apart probe set (Vysis, Downers Grove,
IL). The probe mixture was applied to the slides, which were
then incubated in a humidified atmosphere with HYBrite
(Vysis) at 77°C for 5 minutes to simultaneously denature the
probe and target DNA. An additional 16-hour incubation at
37°C was required for hybridization. Next, the slides were
immersed in 0.3% NP-40/0.4 SSC for 5 minutes at room
temperature, followed by 0.3% NP-40/0.4 SSC for 5 min-
utes at 72°C. Nuclei were counterstained with DAPI (4,6-
diamidino-2-phenylindole).
ALK FISH was considered positive when more than
15% of 50 or more analyzed cells showed splitting apart of
the fluorescent probes flanking the ALK locus. Immunohisto-
chemistry (IHC) by a mouse monoclonal antibody for ALK
(Novocastra, Clone 5A4, Newcastle upon Tyne, United King-
dom) was performed using a Bond-max automated immunos-
tainer (Leica Microsystems, Milton Keynes, United King-
dom). Various normal and cancer tissue microarray blocks
were included as positive and negative controls. ALK IHC
was considered positive if moderate staining was identified in
10% or more of the tumor cells.19 The EGFR mutation, ALK
break-apart FISH, and ALK IHC were analyzed by experi-
enced pathologists (Y.-K.J., D.H.C., and W.-H.K.).
Pemetrexed Treatment and Response
All patients received pemetrexed alone at a dose of 500
mg/m2 every 21 days. Folic acid supplementation (1000 mg)
was taken orally daily beginning 1 to 2 weeks before the first
dose of pemetrexed and continued until 3 weeks after treat-
ment ended. Dexamethasone (4 mg) was taken twice daily on
the day before, the day of, and the day after each dose of
pemetrexed. An injection of vitamin B12 (1000 g) was given
1 to 2 weeks before the first dose of pemetrexed and was
repeated approximately every 9 weeks during treatment.
Treatment was continued until disease progression warranted
termination, unacceptable toxicity was found, or until the
patient or physician decided to discontinue therapy. Tumor
response was evaluated every two cycles, or earlier if there
were clinical signs of progression, by the Response Evalua-
tion Criteria in Solid Tumors version 1.0.20
In Vitro Cytotoxicity of Pemetrexed
A modified MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyltetrazolium bromide) assay was analyzed using CCK-8
(Dojindo, Rockville, MD). The inhibitory concentration at
50% (IC50) was calculated. ALK-positive cells included NCI-
H3122, kindly provided by Pasi A. Ja¨nne at the Dana Farber
Cancer Institute, and NCI-H2228. EGFR mutant cells (PC-9)
were kindly provided by Mayumi Ono at Kyushu University.
ALK-positive cells (NCI-H3122 and NCI-H2228), EGFR
mutant cells (PC-9), WT cells (NCI-H1666), and control cells
(NCI-H157, squamous cell carcinoma) were continuously
exposed to pemetrexed at a concentration of 0.001 to 1 M
for 48 or 96 hours. After 1 hour of incubation at 37°C, the
absorbance was measured at 450 nm in a microplate reader.
TS mRNA expressions of NSCLC tumor cells were quanti-
fied by reverse-transcriptase polymerase chain reaction. All
experiments were repeated three times. A two-sided t test was
used to evaluate group differences.
Statistical Analysis
Analyzed variables include age, sex, performance status,
smoking history, histology, stage, pemetrexed treatment line,
and molecular subtypes. Pearson’s 2 and one-way analysis of
variance tests were performed to assess differences in clinical
and pathological characteristics between the three molecular
subgroups. The association between clinical factors and the
response rate to pemetrexed was analyzed using Pearson’s 2
test or Fisher’s exact test, as appropriate. TTP was calculated
FIGURE 1. Kaplan-Meier plot of time to progression in all
patients.
TABLE 2. Efficacy of Pemetrexed Based on Genotype
Molecular
Subtypes
No. of Patients (%)
p
ALK
Translocation
(n  15)
EGFR
Mutation
(n  43)
Wild Type
(n  37)
Cycle
Median
(range)
9 (1–36) 2 (1–23) 4 (1–33)
Best response
PR 7 46.7 2 4.7 6 16.2
SD 6 40.0 9 20.9 15 40.5
PD 2 13.3 32 74.4 16 43.2
ORR 7 46.7 2 4.7 6 16.2 0.001
DCR (PR  SD) 13 86.7 11 25.6 21 56.8 0.000
Median TTP, mo
(95% CI)
9.2 (4.65–13.74) 1.4 (1.27–1.52) 2.9 (0.51–5.28) 0.001
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; PR,
partial response; SD, stable disease; PD, progressive disease; ORR, overall response
rate; DCR, disease control rate; CI, confidence interval; TTP, time-to-progression.
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from the first date of pemetrexed therapy to the date of
documented progression. Survival curves were plotted by the
Kaplan-Meier method.21 Differences between groups were
compared using the log-rank test. Factors independently as-
sociated with TTP and response to pemetrexed were identi-
fied by multivariate analysis using the Cox’s proportional
hazards regression model and binary logistic regression, re-
spectively. Two-sided p values less than 0.05 were consid-
ered significant. All analyses were performed using SPSS,
version 12.0 (Chicago, IL).
RESULTS
Patients and Molecular Subtypes
Of 142 NSCLC patients who were treated with pem-
etrexed alone and underwent molecular screening for EGFR
or ALK, 95 met the study inclusion criteria. Patients were
segregated into EGFR mutant (n  43), ALK-translocated
(n  15), and WT (n  37) groups. Twenty-five patients had
an exon 19 deletion, whereas 18 patients harbored an L858R
mutation. Baseline characteristics are summarized in Table 1.
FIGURE 2. Kaplan-Meier plots of time to
progression in patients treated with second-
line pemetrexed (A) and in those treated
with third-line pemetrexed and beyond (B).
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There were no significant differences between the groups
with respect to sex, performance status, smoking history,
histology, and stage. ALK-positive patients were younger
than others (p  0.043). Regarding treatment line, more
patients with WT and ALK translocation received pemetrexed
as a second-line treatment than those with EGFR mutation
(p  0.001). Of 43 EGFR-mutant patients, 39 (90.7%)
received EGFR TKIs before pemetrexed treatment.
Efficacy of Pemetrexed
After a median follow-up of 11.2 months (range, 0.9–
39.3) from the start of pemetrexed treatment, 44 patients were
still alive. Five patients continued to receive pemetrexed at
the cutoff date for data collection (November 30, 2010). All
patients could be evaluated for tumor response and treatment
outcomes based on subtypes were described in Table 2. ORR
was 15.8%, whereas DCR (partial response [PR]  stable
disease [SD]) was 47.4%. Response rates were similar be-
tween second-line and third-line pemetrexed groups (ORR,
21.1 versus 12.3%, p  0.251; and DCR, 52.6 versus 43.9%,
p  0.402, respectively). The median TTP in all patients was
2.2 months (95% confidence interval [CI]: 1.36–3.03).
There was no significant difference in TTP between
second-line and  third-line pemetrexed groups (2.7 versus
1.7 months; p  0.618). Patients with ALK translocation
showed higher response rates than those with EGFR mutation
or WT (Table 2). In 38 patients treated with second-line
pemetrexed, ALK-positive patients showed higher response
rates, compared with EGFR mutated and WT patients (ORR,
50.0 versus 0 versus 19.2%; p 0.096; and DCR, 83.3 versus
16.7 versus 53.8%; p  0.067, respectively). For the  third-
line pemetrexed group (57 patients), ORR and DCR were
significantly higher in ALK translocation patients than in
EGFR mutation and WT patients (ORR, 44.4 versus 5.4
versus 9.1%; p  0.006; and DCR, 88.9 versus 27.0 versus
63.6%; p  0.001, respectively). ALK positivity was the only
significant factor correlated with favorable ORR in univariate
(p  0.001) and multivariate analyses (hazard ratio [HR] 
0.07, 95% CI: 0.01–0.32; p  0.001).
ALK-translocated patients showed superior TTP com-
pared with EGFR mutant or WT patients (regardless of
treatment line, 9.2 versus 1.4 versus 2.9 months, p  0.001,
Figure 1; and third line or beyond, 6.4 versus 1.4 versus 4.0
months, p  0.003, Figure 2B). Second-line pemetrexed
tended to prolong TTP in NSCLC patients with ALK trans-
location as compared with those with EGFR mutation and
WT (9.2 versus 1.3 versus 2.7 months; p 0.224, Figure 2A).
ALK positivity was a significant predictor for TTP, as deter-
mined by univariate (p  0.004) and multivariate analyses
(HR 0.44, 95% CI, 0.24–0.80; p  0.007). ALK positivity
remained independently significant in treatment-line stratified
multivariate analysis (HR  0.43, 95% CI: 0.24–0.77; p 
0.005). Other clinical and pathologic factors were not predic-
tive of TTP (p 0.05). Treatment outcomes of pemetrexed in
ALK-translocated NSCLC are detailed in Table 3. At the time
of data cutoff, 11 patients were alive and the median overall
survival had not been reached.
In Vitro Cytotoxicity of Pemetrexed
Although the IC50 values (mean  SD) were signifi-
cantly lower in ALK-positive cells (H3122, 68.7  21.1 nM;
H2228, 33.0  10.7 nM) than in control cells (H157, 1
M), there were no statistical differences between ALK-
positive cells and WT cells (H1666, 50.9  30.2; Figure 3A).
The TS/GAPDH mRNA ratio of ALK-positive cells (H3122,
0.13  0.10; H2228, 0.48  0.08) was significantly lower
TABLE 3. Summary for ALK-Positive NSCLC Patients
Pt
Age
(yr) Sex Histology
Smoking
(Pack-Year) Surgery
RFS
(mo)
Pemetrexed
OSb
(mo) StatusLinex Cycle BR TTP (mo) OSa (mo)
1 52 F Ad 0 5 24 PR 17.6 39.3 133.9 Alive
2 49 F Ad 25 Yes 16 2 6 SD 4.8 25.4 46.1 Death
3 45 M Adc 20 3 36 PR 28.0 35.2 60.4 Alive
4 54 M Ad 20 Yes 109 5 23 SD 22.6 34.3 263.3 Alive
5 34 M NSCLC, NOS 10 6 13 SD 9.7 33.6 62.9 Alive
6 64 M Ad 0 3 6 SD 6.1 31.3 38.3 Alive
7 67 M Ad 0 2 9 PR 15.5 25.6 34.8 Alive
8 60 F Ad 0 Yes 17 3 5 SD 5.0 24.7 52.4 Alive
9 48 F Ad 0 4 6 PR 4.6 22.5 30.6 Death
10 54 M Ad 30 3 2 PD 1.3 10.5 19.6 Death
11 63 M Ad 17 2 22 PR 15.9 17.9 23.3 Alive
12 55 F Ad 20 2 12 SD 9.2 13.1 61.5 Alive
13 49 F Ad 0 2 1 PD 0.5 12.9 20.0 Alive
14 51 F Adc 0 2 15 PR 11.7 11.7 17.7 Death
15 43 F Ad 0 Yes 49 3 9 PR 6.4 7.5 75.8 Alive
a The time from the first date of pemetrexed treatment to the date of death or the last visit of the patient.
b The time from diagnosis to the date of death or the last visit of the patient.
c Adenocarcinoma with signet ring cell component.
Pt, patient; RFS, relapse-free survival; BR, best response; Ad, adenocarcinoma; SRC, signet ring cell; NSCLC NOS, non-small cell lung cancer not otherwise specified; TTP,
time to progression.
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compared with that of control cells (H157, 0.60  0.10;
Figure 3B). However, the TS/GAPDH mRNA ratio was
similar between H2228 and ALK-negative cells (PC9, 0.51 
0.11; H1666, 0.35  0.06).
DISCUSSION
Our study demonstrates that pemetrexed treatment pro-
duced significantly better outcomes in ALK-translocated
NSCLC patients than in EGFRmutant or WT patients. DCRs,
as well as overall response rates, were excellent in ALK-
positive patients (86.7% of DCR and 46.7% of ORR). In
addition, median TTP was nearly sixfold higher in ALK-
positive NSCLC than in ALK-negative patients. ALK positiv-
ity alone was an independent predictor for the efficacy of
pemetrexed treatment.
EGFR TKIs were ineffective in treating ALK-rear-
ranged NSCLC.7 However, pemetrexed significantly delayed
TTP in ALK-positive patients compared with ALK-negative
patients. Considering that the median progression-free sur-
vival times of NSCLC is 2.9 months when pemetrexed is
used as a second-line therapy13 and 3.0 months as a third-line
treatment,15 it is encouraging that ALK-positive patients re-
mained progression-free at 9.2 months with second-line pem-
etrexed treatment and 6.4 months for third- or greater-line
treatment in this study. Furthermore, the response rate to
pemetrexed in ALK-positive NSCLC was more than 45%,
which is superior to the ORR of 9.1 to 12.1% in the litera-
ture.13,15 Disease was controlled in approximately 90% of
ALK-positive patients after pemetrexed, regardless of treat-
ment line.
In addition, two of four patients relapsed at 49 and 109
months after surgery and survived for more than 6 and 21
years, respectively. This is comparable with published reports
of disease-free intervals of 73 months22 and 20 years23 in
ALK-positive Japanese patients. This indicates an indolent
clinical course. Less differentiated tumor grade and a low
frequency of p53 mutations might reflect favorable prognosis
in EML4-ALK translocated NSCLC.24
Because cytotoxicities of pemetrexed are similar in
lung adenocarcinoma cells regardless of ALK positivity, an
indolent clinical course rather than a direct cytotoxic effect of
pemetrexed may be the mechanism by which pemetrexed
prolongs survival time in ALK-positive NSCLC.
Recently, a heat-shock protein 90 (HSP90) inhibitor
was found to suppress ALK-translocated NSCLC, both pre-
clinically25 and in an early-phase clinical trial.26 The HSP90
inhibitor reduced EML4-ALK-driven tumor by disrupting
phospho (p)-AKT and p-ERK 1/2 signals.25
Although the effect of pemetrexed on HSP90 is un-
known, pemetrexed significantly downregulated p-AKT in
NSCLC cells.27 Therefore, pemetrexed may work on ALK-
rearranged NSCLC cells by suppressing a downstream signal,
p-AKT, shared by ALK. However, the exact mechanism of
pemetrexed on ALK-translocated NSCLC cells is unknown.
In addition, the role of first-line or maintenance pemetrexed
should be resolved, even though pemetrexed plus cisplatin
significantly prolonged survival in ALK-positive NSCLC pa-
tients.17 Efficacy of pemetrexed in ALK-positive NSCLC will
be shown as a second-line treatment (NCT00932893)28 and
first-line combination chemotherapy (NCT01154140).29
High TS expression has been considered as a resistance
mechanism in NSCLC30–32 and may be a predictive bio-
marker of pemetrexed sensitivity. TS mRNA levels were
relatively low in ALK-positive cells in our study. However, it
is difficult to conclude the mechanism of pemetrexed sensi-
tivity based on TS mRNA levels because of the lack of TS
evaluation in tumor tissue. However, ALK positivity can be a
predictive biomarker for pemetrexed sensitivity in NSCLC in
nonsquamous histology. Reversely, pemetrexed effectiveness
can be used as one of selection criteria for ALK screening in
lung cancer. Retrospective analysis of response to chemother-
apy and prospective tracking of a small number of ALK-
positive patients may weaken the association between pem-
etrexed sensitivity and ALK positivity in NSCLC. However,
FIGURE 3. In vitro cytotoxicity of pemetrexed (A) and
thymidylate synthase mRNA level (B) in non-small cell
lung cancer cells.
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it is worthwhile to elucidate the efficacy of pemetrexed based
on the molecular subtypes.
In conclusion, pemetrexed significantly delayed TTP
and showed excellent antitumor effects in patients with ALK-
translocated NSCLC. ALK positivity could be a predictive
biomarker for pemetrexed efficacy in patients with NSCLC.
Nevertheless, caution is warranted in interpreting these find-
ings, because of the unbalanced number of patients treated
with pemetrexed in the EGFR mutant group. This can be
attributed to the second-line use of EGFR TKIs in most cases.
Future studies should focus on determining the mechanism of
pemetrexed action on ALK-positive NSCLC. Moreover, the
efficacy of pemetrexed in ALK-positive patients needs to be
further investigated using prospective clinical trials.
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